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Severe Renal Impairment and
Stroke Prevention in Atrial Fibrillation
Implications for Thromboprophylaxis and Bleeding Risk
Ricarda Marinigh, MD,*† Deirdre A. Lane, PHD,* Gregory Y. H. Lip, MD*
Birmingham, United Kingdom; and Trieste, Italy
The prevalence of atrial fibrillation (AF) in end-stage renal failure is high, with an increased risk of stroke among
these patients with AF compared with the AF population without severe renal impairment. Many trials have
shown the net clinical benefit of oral anticoagulation therapy for primary and secondary prevention of stroke in
patient populations with AF. However, current stroke risk stratification schemes are based on studies that have
deliberately excluded patients with severe renal impairment. Indeed, there are no large randomized controlled
trials that assess the real risk/benefit of full intensity anticoagulation in patients with severe renal impairment.
Also, rates of major bleeding episodes in anticoagulated hemodialysis patients with AF are high. These data are
influenced by the lack of appropriate monitoring, the difficulties in maintaining the international normalized ra-
tio target (variable between the studies), and an inaccurate bleeding classification. Thus, the limited available
data may be difficult to apply to such a heterogeneous patient population, characterized by both an increased
risk of bleeding and a hypercoagulability state, as seen in the patient population with severe renal impairment.
(J Am Coll Cardiol 2011;57:1339–48) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.12.013The frequency of atrial fibrillation (AF) in patients with
end-stage renal failure is 10- to 20-fold higher than in the
general population (1–3), although significant variability in
the prevalence exists between the studies, ranging from 7%
to 27% (1–4), and is largely dependent on demographic
characteristics, duration of renal replacement therapy, and
method of AF detection. In the CRIC (Chronic Renal
Insufficiency Cohort) study, for example, nearly 1 in 5
participants had evidence of AF at study entry, a prevalence
similar to that reported among patients with end-stage renal
failure (3). Also, the large U.S.-based Renal Data System
reported an AF prevalence of 13% in patients on hemodi-
alysis and 7% in patients undergoing peritoneal dialysis (4).
Both AF and severe renal impairment are age-dependent
(3–6), but studies also report an increased prevalence of AF
in patients with chronic kidney disease (defined as reduced
glomerular filtration rate and/or proteinuria) (7), compared
to age- and sex-matched people with normal renal function
(8). As the long-term dialysis patient population grows
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population (9–12).
In the population with severe renal impairment, AF
detection is related to the diagnosis of ischemic heart disease
and degenerative valvular heart disease (13), as well as
accelerated vascular calcification and the presence of left
ventricular hypertrophy (14,15). There is also an intimate
relationship to hypertension, given the strong inter-
relationships of the latter to AF and renal dysfunction, as
reflected by the high incidence of microalbuminuria (an
early indicator of renal “dysfunction”) in hypertensive pa-
tients with AF (16). Other reported risk factors for the
development of AF in patients with severe renal impairment
are the fluctuating electrolytes levels during hemodialysis,
sympathetic nervous system activation, and modulation of
the renin angiotensin system (1). In patients with severe
renal impairment who are on dialysis (i.e., end-stage renal
failure), cardiovascular disease annual mortality rates are 9%
(17), 5 to 30 times higher than in subjects from the general
population of same age, sex, and ethnicity (17,18).
Search Strategy
We performed a comprehensive literature search by using elec-
tronic bibliographic databases (i.e., MEDLINE, EMBASE, the
Database of Abstracts of Reviews of Effects [DARE], and the
Cochrane Database of Systematic Reviews), scanning reference
lists from included articles and hand searching abstracts from
national and international cardiovascular meetings. For the
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term atrial fibrillation plus 1 or
more of the following: renal failure,
renal dysfunction, end-stage renal
failure, dialysis, hemodialysis, stroke,
bleeding/hemorrhage, stroke pre-
vention, and thromboprophylaxis.
Where necessary, study authors
were contacted to obtain further
data. Only studies with clearly de-
fined populations with “severe re-
nal impairment” were included.
Chronic kidney disease is a
broad term, and so we have tried to avoid its use as far as
possible. Instead we have used the term severe renal impair-
ment as defined in recent clinical trials as a creatinine
clearance of 30 ml/l and end-stage renal failure to mean
severe renal impairment with the necessity for renal dialysis.
Clearly, severe renal impairment with dialysis ( end-stage
renal failure) may have many differences in comorbidities,
drugs, and nondrug interventions compared with patients
with severe renal impairment without dialysis. Given that
there is a vast amount of literature of relatively poor general
quality, we have essentially done a semi-systematic review of
the published reports, rather than conduct a formal
Cochrane-style systematic review and critical appraisal.
Risk of Stroke in Severe Renal Impairment
The major complication of AF is ischemic stroke and
thromboembolism, and some studies (11,15,19,20) have
demonstrated that the presence of AF increases the risk of
stroke in dialysis patients, although other studies have not
reported this association (21–24) (Table 1).
In a recent large prospective cohort study of AF patients,
Go et al. (25) found that a lower level of estimated
glomerular filtration rate (eGFR) was associated with a
graded, increased risk of ischemic stroke and other systemic
embolism, independently of known risk factors in AF. The
adjusted hazard ratio (HR) for thromboembolism was 1.39
(95% confidence interval [CI]: 1.13 to 1.71) and 1.16 (95%
CI: 0.95 to 1.40) for an eGFR 45 ml/min and eGFR of
45 to 59 ml/min, respectively, compared with an eGFR
60 ml/min (25). Another study by Vazquez et al. (15)
demonstrated that the risk of ischemic stroke was 4.75 per
100 patient-years among patients undergoing dialysis who
had AF compared with 0.48 per 100 patient-years in those
who maintained sinus rhythm during dialysis. Therefore,
AF was associated with a 9.8-fold increased risk of stroke
among dialysis patients (15). However, a previous study
performed in the same center reported a 4.6-fold (95% CI:
2.4 to 8.6) increased relative risk of developing a thrombo-
embolic event (19). The elevated risk of stroke in the more
recent study by Vazquez et al. (15) may be explained by the
Abbreviations
and Acronyms
AF  atrial fibrillation
CI  confidence interval
eGFR  estimated
glomerular filtration rate
HR  hazard ratio
INR  international
normalized ratio
TIA  transient ischemic
attackinclusion of older patients (65 years vs. 57 years) with thepresence of more comorbidities (elevated body mass index,
hypertension, 30% with diabetes, 10% with bundle branch
block, half with echocardiographic parameters of dilated left
atrium and heart calcification), compared with their earlier
study (19).
These variables have been shown to be closely associated
with AF in the general population, and complicate the
evaluation of the influence of renal insufficiency per se on
stroke risk, in the presence of AF (19). In the U.S. Renal
Data System study, patients with end-stage renal failure and
AF had a 1.8-fold higher rate of ischemic strokes, whereas
hemorrhagic stroke rates were comparable to end-stage
renal failure patients in sinus rhythm (20). Conversely, in
the Rotterdam study, decreased GFR did not significantly
increase the risk of ischemic stroke (HR: 1.25; 95% CI: 0.97
to 1.61), but was a strong predictor of hemorrhagic stroke
(HR: 3.02; 95% CI: 1.45 to 6.27) (22).
The discrepancy between studies that report an associa-
tion between AF and ischemic stroke in hemodialysis
patients (19) and studies that do not report such an
association (21,22), may be partly explained by the
follow-up period studied. For example, Genovesi et al. (21)
considered presentation of a stroke within the overall 3-year
follow-up period, and did not consider that the high
mortality rate of patients on hemodialysis would reduce the
time of exposure risk, whereas Vazquez et al. (19) consid-
ered only the period in which the patients were followed up.
Furthermore, there may be underdiagnosis of (asymptom-
atic) AF in hemodialysis patients, perhaps due to a lack of
accurate continuous rhythm monitoring.
Thromboembolism in AF and
Severe Renal Impairment:
Pathophysiological and Clinical Observations
The presence of AF per se confers a hypercoagulable state
(26) through various pathways. Virchow’s triad of abnor-
malities that predispose to thrombus formation, flow abnor-
malities (secondary to blood stasis in the left atrium) (26),
abnormalities of the vessel wall (endothelial and endocardial
damage and dysfunction, and increased expression of tissue
factor and von Willebrand factor) (26) and abnormal blood
constituents (increased platelet activation and fibrinolysis)
(26) are fulfilled in AF, resulting in this arrhythmia confer-
ring a prothrombotic or hypercoagulable state.
Patients with end-stage renal failure treated with chronic
dialysis without AF are also at increased risk of thrombo-
embolic events due to the alteration of many physiological
mechanisms that lead to substantial changes in hemostasis.
These are represented by increased atherosclerosis and
endothelial damage, alteration in protein C metabolism,
defects in the expression of glycoprotein (GP) Ib, elevated
plasminogen activator inhibitor-1 to tissue-type plasmino-
gen activator ratios, and inhibition of plasmin by increased
levels of lipoprotein(a) (1,27). For example, Tanaka et al.
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antithrombin (TAT) and fibrin D-dimer levels (both in-
dexes of thrombogenesis). In another study, renal insuffi-
ciency was independently associated with elevations in
inflammatory and procoagulant biomarkers (29). These
findings lend support to the notion that enhanced coagula-
tion activation appears to be related to a reduction in
residual renal function in patients with AF (27).
Clinically, the combination of end-stage renal failure and
AF in patients treated with chronic hemodialysis may confer
significantly greater thromboembolic risk. For example,
Vazquez et al. (12) demonstrated that approximately one-
third of hemodialysis patients with AF have thromboem-
bolic complications within 1 year of follow-up. Given the
high risk for thromboembolic complications, we would
perhaps assume that hemodialysis patients with AF may
benefit from warfarin therapy.
A study by Chan et al. (30) investigated the association
between the use of warfarin, clopidogrel or aspirin and new
stroke, mortality, and hospitalization in a retrospective
cohort analysis of 1,671 incident hemodialysis patients with
pre-existing AF (mean follow-up of 1.6 years). Compared
with non-warfarin users, warfarin use was associated with a
significantly increased risk for new stroke (HR: 1.93; 95%
CI: 1.29 to 2.90) without an increase in all-cause mortality
or hospitalization, whereas clopidogrel or aspirin use was
not associated with increased risk for new stroke. However,
this study has some limitations, as follows: 1) the highest
risk for stroke in warfarin users compared with nonusers was
more evident in those who received no international nor-
malized ratio (INR) monitoring in the first 90 days of
dialysis (HR: 2.79; 95% CI: 1.65 to 4.70); 2) a higher
percentage (29%) of patients who were on warfarin and
survived their stroke stopped the drug on discharge from
hospital, which suggests a reasonable number of strokes
were likely to be hemorrhagic in nature, or intracranial
hemorrhages; 3) the increase in strokes among warfarin
users may have been due to anticoagulation, with higher
INR levels that may have led to an inherently higher
baseline stroke risk that was not fully adjusted for by
covariates, such as the CHADS2 score; and 4) INR record-
ings were not accurately reported (30). Hence, these data
need to be interpreted with a little caution, but would still
illustrate the “fragile” nature of this high-risk patient pop-
ulation. Indeed, Wizemann et al. (31) also reported that
warfarin use in patients with AF was associated with a
significantly higher stroke risk, particularly in those over 75
years of age.
In summary, the presence of end-stage renal failure is
associated with increased thromboembolism, partly in rela-
tion to greater coagulation and platelet abnormalities, but
the various comorbidities associated with end-stage renal
disease (e.g., hypertension, diabetes, and so on) may well be
contributory.Bleeding Risk in Severe Renal Impairment:
Pathophysiological and Clinical Observations
Observational data has underlined the increased risk of
bleeding complications (especially gastrointestinal bleeding)
exacerbated further by heparin anticoagulation with each
dialysis treatment (32). Gastrointestinal bleeding, with re-
current episodes and multiple bleeding sites, occurs with
greater frequency and is associated with higher mortality in
uremic than in nonuremic patients, with upper gastrointes-
tinal bleeding accounting for 3% to 7% of all deaths in
patients with end-stage renal failure (32,33).
Clinically and pathophysiologically, patients with severe
renal impairment at all stages of the disease have increased risk
factors for bleeding (1). Pathophysiological reasons include
platelet abnormalities, reduction in intracellular ADP and
serotonin, impaired release of the platelet alpha-granule pro-
tein and beta-thromboglobulin, enhanced intracellular cAMP
and abnormal mobilization of platelet Ca2, abnormal platelet
arachidonic acid metabolism, defective cyclo-oxygenase activ-
ity, abnormality of the activation-dependent binding activity of
GP IIb/IIIa, increased formation of vascular PGI2, and altered
von Willebrand factor (1). An increased risk of hemorrhage in
uremic patients is also related to uremic toxins, especially
parathyroid hormone, altered blood rheology (anemia), eryth-
ropoietin deficiency, and the use of specific treatments (e.g.,
nonsteroidal anti-inflammatory drugs). Furthermore, this pop-
ulation frequently needs to undergo invasive procedures (i.e.,
biopsies) that increase the bleeding risk. In a retrospective
cohort of patients discharged from hospital on warfarin
therapy, for example, severe renal impairment was inde-
pendently identified as a risk factor for subsequent major
hemorrhage (34).
In summary, end-stage renal disease can also be related to
more bleeding related to functional abnormalities within
platelets and other pathways, as well as to other factors, for
example, toxins, uncontrolled hypertension, repeated can-
nulations for dialysis, and so on.
Oral Anticoagulants in Severe Renal Impairment
The management of chronic dialysis patients with AF with
warfarin is controversial as there is no evidence base for this
therapy, given that the proposed stroke risk stratification schemes
are based on studies that actively excluded end-stage renal failure
patients (35–41). The majority of trials employed renal function
exclusion criteria, most typically serum creatinine 3 mg/dl or a
creatinine clearance of 30 ml/min (i.e., RE-LY [Randomized
Evaluation of Long Term Anticoagulant TherapY] [42]). How-
ever, some novel anticoagulant trials (ROCKET-AF [Rivaroxa-
ban with adjusted-dose Oral warfarin for the prevention of stroKE
in paTients with Atrial Fibrillation] [43], ARISTOTLE [Apixa-
ban for Reduction In STroke and Other ThromboemboLic
Events in atrial fibrillation] [44]) have a lower dose of the study
drug available to randomize patients with serum creatinine 1.5
g/l (plus either age 80 years or weight 60 kg), in the
Warfarin Use in Patients With Severe Renal Impairment or End-Stage Renal Failure (on Dialysis)Table 1 Warfarin Use in Patients With Severe Renal Impairment or End-Stage Renal Failure (on Dialysis)
First Author
Year (Ref. #) Study n Population Indication
Follow-Up,
months INR Warfarin/Control
Bleeding Events/
Pt-Yrs Thromboembolic Events
Mokrzycki et al.
2001 (56)
RCT 85 HD
Newly placed
TCC
Prevention of catheter
thrombosis
12 Fixed dose 1 mg 41 warfarin
44 control
1 event/165 (0.06)
1 event 18.4 (0.05)
No benefit of warfarin on
thrombosis-free
catheter survival
Coli et al.
2006 (57)
RCT 144 HD Prevention of TCC thrombosis
(early vs. delayed initiation
of warfarin-after first cloth)
12 1.8–2.5
1.8–2.5
63 warfarin
81 (250 mg
ticlopidine)
† 10/81 (12)
33/63 (52)
Biggers et al.
1977 (47)
Retrospective
cohort study
125 HD Prevention recurrent Scribner
external A-V shunt
thrombosis
84 Target prothrombin
time 2 control
value
48 warfarin
77 control
50 major events/
94 (0.5)
9 events/
360 (0.025)
†
LeSar et al.
1999 (51)
Case series 12 HD Prevention of recurrent PTFE
graft thrombosis
24 2.7–3.0 10 warfarin
2 control
4 events/40 (0.1)
†
1.2 events/yr
4.0 events/yr
Vazquez et al.
2000 (12)
Prospective 190 HD
AF 13.6 pt-yrs
Investigate consequences of
AF on morbido-mortality of
patients on hemodialysis
12 Warfarin in AF
Not reported
† Stroke
23.2 (6/26) AF
4.3 (7/164) non-AF
Wiesholzer et al.
2001 (23)
Retrospective 125 HD
AF 14.2 pt-yrs
Assess incidence of stroke
and AF in HD patients
(anticoagulants)
1.11–1.16 pt-yrs AF 14.2 pt-yrs
warfarin
† Stroke (pt-yrs):
3.78 (total)
4.46 (AFOAC)
1.0 AF (AFOAC)
2.8 (AF)
Vazquez et al.
2003 (50)
Observational
cohort study
240 214 HD
24 PD
Prevention of thrombosis or
embolism in AF, valve
prosthesis, or rheumatic
valvulopathy, endovascular
stent, pulmonary
embolism, or
cerebrovascular accident
20
21
† 29 warfarin
211 control
13 major events/
49 (0.26)
39 events/
369 (0.11)
RR: 2.36
95% CI: (1.19–4.27)
†
O’Shea et al.
2003 (52)
Case series 29 HD Prevention of recurrent PTFE
graft thrombosis
8.6 2.0–3.0 13 warfarin
12 UHF (6,000
twice daily)
11 LMWH
(enoxaparin
30–40 mg/day)
5 events/9.3 (0.54)
3 events/8.6 (0.35)
2 events/7.9 (0.25)
2 graft failure
3 graft failure
5 graft failure
Obialo et al.
2003 (58)
Nonrandomized,
nonblinded,
prospective
trial
63 HD Prevention of TCC thrombosis 36 2.0–3.0 11 warfarin
21 aspirin 325 mg
2
0
Abbott et al.
2003 (14)
USRDS
administrative
database
3,374 HD
AF 12.5/1,000
person years*
1.25*
Evaluate incidence and risk
factors for hospitalized AF
in a population of dialysis
patients
48 AF 8.1 pt-yrs
warfarin
† Stroke 3.0 (AF)
Continued on next page
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in the ROCKET-AF trial (43). Given that patients with end-
stage renal disease have a much higher risk of stroke than the
general population, it would be reasonable to assume that AF
patients with end-stage renal disease have an even higher risk
of stroke than those without end-stage renal disease.
The current consensus of opinion is that there is an elevated
hemorrhagic risk with anticoagulant therapy in end-stage renal
failure patients on chronic dialysis (33,45–47), with some studies
considering hemodialysis as a contraindication to warfarin (23).
Warfarin has a further additional adverse effect on hemodial-
ysis patients. Acting as a vitamin K antagonist, warfarin
reduces the function of endogenous vitamin K–dependent
inhibitors of calcification, such as the matrix Gla protein,
therefore facilitating vascular calcification, at least in experi-
mental studies (48). Some case reports have also demonstrated
an association between warfarin use and the development of
calcific uremic arteriopathy (49).
The bleeding risk associated with anticoagulation use in
hemodialysis patients has been demonstrated by some ob-
servational studies (14,46,50–55), but few have addressed
the risk-benefit of warfarin for stroke thromboprophylaxis
in the hemodialysis population with AF. Most studies
(47,51–53,56–59) evaluated warfarin use to prevent access
thrombosis, the most frequently identified thrombotic event
in the maintenance of hemodialysis patients. Therefore, the
potential benefit of warfarin for stroke prevention in the
hemodialysis population with AF may be underestimated.
One observational study, based on U.S.-based Renal Data
Service DMMS Wave 2 (Dialysis Morbidity and Mortality
Wave 2 Study) data of 123 hemodialysis patients hospital-
ized for AF, demonstrated that only the use of warfarin and
a systolic blood pressure130 mm Hg were associated with
increased survival (14).
A recent systematic review of warfarin use in hemodial-
ysis patients noted that major bleeding rates ranged from
0.10 to 0.54 events per patient-year of warfarin exposure,
twice as high as those of hemodialysis patients receiving
either no warfarin or subcutaneous heparin (55). However,
the 4 studies evaluating full-intensity anticoagulation were
either observational cohort studies or case series involving
hypercoagulable hemodialysis patients, and these results
have not been confirmed in a randomized controlled trial
evaluating dose-adjusted warfarin for any indication in
patients with severe renal impairment.
In the cohort studies, where the incidence of major
bleeding episodes was at least double that of patients
exposed to intradialysis heparin only, a lack of INR control
and appropriate monitoring may have contributed to the
excess bleeding risk in patients on warfarin (55).
Overall, the type and severity of comorbid illnesses were
the most important risk factors for anticoagulant-related
bleeding. Cardiovascular disease, liver dysfunction, and
severe renal impairment were associated with increased risk
of bleeding (55). Concurrent intake of antiplatelet agents,
especially aspirin, also increased the risk of anticoagulant-Co T Z
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hemodialysis patients by Vazquez et al. (50), the risk of
hemorrhage without anticoagulation was high (11 episodes/
100 patient-years), but this risk of bleeding was more than
doubled on warfarin therapy (26 episodes per 100 patient-
years; relative risk: 2.36, 95% CI: 1.19 to 4.27). However,
this risk of hemorrhage was usually confined to the digestive
tract, which was nonfatal, rather than the debilitating
intracranial hemorrhage, and there were no serious clinical
sequelae (50). Recently, Holden et al. (54) completed a
retrospective review of 255 patients who were undergoing
hemodialysis and found major bleeding rates of 3.1% and
0.8% for patients receiving warfarin and those not receiving
therapy, respectively.
Therefore, the true bleeding risk associated with the use
of warfarin in hemodialysis patients remains unknown,
given the reliance on small observational studies with
potential confounding by comorbid conditions (54). Fur-
thermore, many of the studies assessing hemorrhagic risk
were performed many years ago (47), and changes in
management of patients with severe renal impairment over
the last 20 years may affect the interpretation of these
studies.
In a recent analysis, Limdi et al. (59) studied 578
patients, evaluating the influence of kidney function on
warfarin dosage, anticoagulation control, and risk of
hemorrhagic complications. AF was an indication for
warfarin (patients could have 1 indication) in 134
(40%), 99 (56.2%), and 23 (43.4%) patients with an
eGFR 60 ml/min, 30 to 50 ml/min, and 30 ml/min,
respectively. This study demonstrated that patients with
severe renal impairment (eGFR 30 ml/min/1.73 kg/m2)
required significantly lower warfarin doses (warfarin dosage
requirements stratified by GFR were 4.8 mg/day [4.6 to 5.0
mg/day], 4.3 mg/day [4.0 to 4.6 mg/day], and 3.9 mg/day
[3.5 to 4.4 mg/day] with an eGFR 60 ml/min, 30 to 50
ml/min, and 30 ml/min, respectively, p  0.0002) com-
pared with patients with no, mild, or moderate renal
impairment, independent of CYP2C9 and VKORC1 ge-
notype (59). Furthermore, this study showed that patients
with severe renal impairment spent less time within the
therapeutic INR target range (INR: 2.0 to 3.0) and were at
a higher risk for over-anticoagulation (INR 4.0; p 
0.052) (60). Indeed, the proportion of INR in target range
as stratified by eGFR 60, 30 to 50, and 30 ml/min, was
49.7%, 45.7%, and 45.6%, respectively (p  0.049) (59).
Further, patients with severe renal impairment had a 2.4-
fold (95% CI: 1.1 to 5.3) increased risk of major hemor-
rhage compared with patients with lesser degrees of renal
dysfunction (59). According to these results, diminished
renal function may have implications for a larger proportion
of warfarin users than previously estimated. Therefore, the
relative contraindication for oral anticoagulation in patients
on dialysis programs should be carefully assessed on an rindividual patient basis, in view of the potential benefits of
anticoagulant therapy.
Risk Stratification Schema for Stroke
and Bleeding in Patients With AF and CKD
For the majority of patients with nonvalvular AF, stroke risk
stratification is commonly used, and the most popular
schema is the CHADS2 score (60). The CHADS2 score,
hich is an amalgamation of the risk factors used in the
trial Fibrillation Investigators and the Stroke Prevention
n Atrial Fibrillation Investigators stroke risk schema, as-
igns 1 point for congestive heart failure, hypertension, age
75 years, and diabetes, and 2 points for stroke/transient
schemic attack (TIA) (60). The CHADS2 score is the basis
of other contemporary stroke risk stratification schema,
including those in international guidelines (61,62). How-
ever, all the published stroke schema do not incorporate
severe renal impairment as 1 of the established stroke risk
factors, given that such patients—although recognized as
being at high stroke risk—have not been studied in clinical
trials, and are also at substantial risk of bleeding, death, and
cardiovascular events.
Severe renal impairment is also not included in the most
recently published stroke risk schema within the new
European Society of Cardiology guidelines, the CHA2DS2-
VASc score (63,64). The latter is an acronym that denotes
Cardiac failure or dysfunction, Hypertension, Age 75
years [doubled], Diabetes, Stroke [doubled]–Vascular dis-
ease, Age 65 to 74 and Sex category [female]), whereby 2
points are assigned for a history of stroke or TIA or age75
years, and 1 point each for age 65 to 74 years, a history of
hypertension, diabetes, recent cardiac failure, and vascular
disease (63). Pending validation in appropriate large pro-
spective cohorts, the final letter c in the CHA2DS2-VASc
cronym could possibly be used to informally denote
chronic severe renal impairment” in future refinements of
troke risk stratification, with the caveat that renal function
ay not remain static (and deteriorate over time), especially
n elderly AF patients with multiple comorbidities and
oncomitant drug therapies.
Also, many stroke risk factors are also risk factors for
leeding, and the 3 published bleeding risk schema used in
F cohorts have included renal impairment as a risk factor
65–67). It is important to stress that these bleeding risk
chema have not been formally validated in AF populations
ith severe renal impairment, and much caution is necessary
efore routine application of these bleeding risk scores—
hich were initially proposed for use in the majority of
eneral AF populations seen in everyday clinical practice
64,66,67)—to patients with severe renal impairment and
hose with end-stage renal failure.
Recently, Reinecke et al. (1) presented an individualized
isk stratification algorithm for oral anticoagulation in AF
nd severe renal impairment. A CHADS2 score of 6
epresents an annual average stroke rate of 18.2% (60), but
1345JACC Vol. 57, No. 12, 2011 Marinigh et al.
March 22, 2011:1339–48 Renal Impairment and Stroke in Atrial Fibrillationit has been demonstrated that in unselected patients with
end-stage renal failure and AF, the annual stroke rate ranges
from 17.4% to 24% (19,22), even in the absence of all the
CHADS2 risk factors. This again suggests that CHADS2
risk score may underestimate the stroke risk in renal patients
(1). Therefore, the authors added prosthetic valve disease,
mitral stenosis, and left ventricular impairment to the
CHADS2 classification, and divided stroke risk factors into
“major” (previous stroke or TIA, prosthetic heart valve,
mitral stenosis 2) and “minor” (age, hypertension, diabe-
tes, left ventricular ejection fraction 35%), to decide upon
the indication for warfarin (1 major or 1 minor). In
addition, they added bleeding risk stratification (previous
hemorrhages, liver disease, active malignancies, eGFR 30
Figure 1 Algorithm for Oral Anticoagulation in AF and Chronic
OAC indicates oral anticoagulation, for example, with vitamin K antagonists (VKAs
viable alternatives to the VKAs that are suitable for use in severe renal impairmen
be assessed using the CHA2DS2-VASc score (63,64), although the real stroke risk
tion (essentially warfarin) should be given for those at high stroke risk (e.g., a CHA
months) with no bleeding complications, these patients probably represent a “pos
using a validated scoring system used in the atrial fibrillation (AF) population (e.g.
is likely to be higher than that reported in cohorts with no renal failure, and all pu
severe renal impairment. A HAS-BLED score of 3 would indicate a high enough b
 estimated glomerular filtration rate. Adapted from the algorithm proposed by Reml/min, age75 years, active alcohol abuse, dementia, falls)
to evaluate contraindications to anticoagulation therapy.
According to this classification system, patients who have
already been taking oral anticoagulation for 3 months
without hemorrhage are classified as a “positive selection”
group, with a lower risk of bleeding (1). However, this
algorithm has limited application in aiding decision-making
because the severity of the bleeding risk factors leading to
the contraindication must be evaluated on an individual
patient basis.
Thus, one possible management approach is shown in
Figure 1, partly adapted from the algorithm proposed by
Reinecke et al. (1) (and Lip [68]), and incorporating
approaches to stroke and bleeding risk assessments from
l Disease
t international normalized ratio [INR]: 2.0 to 2.5), but new drugs that may be
ultimately be considered. *Risk factors for stroke and thromboembolism could
ly to be higher than reported in cohorts with no renal failure. Oral anticoagula-
VASc score of 2). If patients have already been taking OAC (e.g., for 3
election” group with a lower bleeding risk. Bleeding risk could be assessed
AS-BLED score [67]), although the real bleeding risk in severe renal impairment
bleeding risk scores have not be specifically validated in an AF population with
g risk to be concerned, whereby regular review and follow-up is necessary. eGFR
et al. (1) and Lip (68), adapted with permission from the latter.Rena
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Renal Impairment and Stroke in Atrial Fibrillation March 22, 2011:1339–48recent guidelines (64). Oral anticoagulation is far superior to
antiplatelet therapy for stroke prevention, and the major
bleeding rate (particularly, fatal bleeding) with aspirin may
be similar to that seen with warfarin (especially in the elderly
[39,64,69]), and aspirin–clopidogrel combination therapy
also confers a major bleeding risk comparable to that seen
with warfarin (70).
Given that AF patients with severe renal impairment are at
high stroke and bleeding risk (71), well-controlled oral antico-
gulation would still be the best option—in the absence of
igh-quality evidence and large prospective randomized clini-
al trials that have specifically investigated this population—
ut regular review and reassessment of risk profile is definitely
eeded. If the patient is taking warfarin, stroke and bleeding
ates can be closely related to quality of anticoagulation control,
o extra efforts to ensure excellent time in therapeutic range
perhaps aiming for a target INR of 2.0 to 2.5) would help offer
he best balance between stroke prevention and bleeding risk (72).
ew oral anticoagulant drugs that can be used in severe renal
mpairment, such as betrixaban (73), may alter our approach to
anaging this complex and high-risk group of patients, but the
enefit and safety of these agents would need to be confirmed
n large prospective clinical trials.
onclusions
he frequency of AF is increased in patients receiving
emodialysis, with a reported prevalence between 7% and
7%, and the presence of AF in patients with severe renal
mpairment is associated with a significantly increased risk
f ischemic stroke (reaching a 9.8-fold increase). However,
here are no large randomized trials that have assessed the
eal risk/benefit of full-intensity anticoagulation in such
atients. Of note, rates of major bleeding episodes in
nticoagulated hemodialysis patients with AF are high.
lso, these data are influenced by the lack of appropriate
onitoring, the difficulties in maintaining the INR target
variable between the studies), and an inaccurate bleeding
lassification. The limited available data may be difficult
o apply to such a heterogeneous patient population
haracterized by both an increased risk of bleeding and
hromboembolism, as seen in the population with severe
enal impairment.
In the future, new oral anticoagulant agents that are
ot affected by renal impairment will hopefully improve
he balance between stroke risk reduction and bleeding
isk in patients with renal impairment, although a specific
linical trial in AF patients with impaired renal function
s warranted (72). For now, oral anticoagulants should
ot be contraindicated in this patient population, but
ather be considered on a patient-by-patient basis (67)
Fig. 1). Warfarin may need to be initiated at a lower
osage and monitored more closely in patients with
evere renal impairment compared with AF patients with
ormal kidney function (24). The regular attendance of
emodialysis patients for each dialysis treatment sessionrovides the opportunity for careful monitoring of pro-
hrombin time ratios, thereby decreasing the risk of major
emorrhage.
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